Related Experiment Video
Updated: Jul 17, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Lenalidomide: immunomodulatory, antiangiogenic, and clinical activity in solid tumors
1Department of Solid Tumor Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA. Dreicer@ccf.org
Abstract:
Lenalidomide is a novel analog of thalidomide with both immunomodulatory and antiangiogenic properties that are more potent than those same properties in the parent compound. Work in several antiangiogenic model systems has provided early evidence of potential mechanisms of its clinical activity. Recent US Food and Drug Administration approval of lenalidomide for patients with deletion 5q myelodysplastic syndromes and advanced multiple myeloma has provided impetus for further evaluation of this agent in solid tumors.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Tumor Immunotherapy
Treatment Resistant Cancers
